MeMed Wins $9.2M DTRA Contract for PoC IVD to Reduce Antibiotic Misuse
Israeli firm MeMed won a contract worth up to $9.2 million from the U.S. Department of Defense (DoD) Defense Threat Reduction Agency (DTRA) to complete the development of a point-of-care in vitro diagnostic platform that can distinguish between bacterial and viral infections, and so help to prevent antibiotic misuse. MeMed’s diagnostic platform uses infection-specific immune [...]